Coherus Oncology (CHRS) reported second-quarter 2026 net revenue from continuing operations of $14.3 million, up from $10.3 million a year earlier. The company posted a net loss from continuing operations of $33.3 million, or $0.22 per diluted share, compared with a $44.9 million loss, or $0.39 per diluted share, in the prior-year period.
LOQTORZI net revenue was $13.6 million in Q2 2026, up 37% from Q2 2025 and 15% from Q1 2026. Coherus said clinical data continue to mature across its pipeline, with initial data readouts expected in the second half of 2026 and projected public disclosure of sufficiently mature data sets in October.
- Q2 2026 net revenue from continuing operations was $14.3 million.
- LOQTORZI revenue was $13.6 million, compared with $10.0 million in Q2 2025 and $11.8 million in Q1 2026.
- Net loss from continuing operations was $33.3 million, or $0.22 per diluted share.
- Cash, cash equivalents and marketable securities totaled $105.3 million as of June 30, 2026.
- Enrollment is complete in the randomized Phase 2 trial of casdozokitug, toripalimab and bevacizumab in first-line unresectable hepatocellular carcinoma.
$CHRS Hedge Fund Activity
We have seen 78 institutional investors add shares of $CHRS stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. added 2,250,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,802,500
- TWO SIGMA INVESTMENTS, LP added 1,798,126 shares (+356.9%) to their portfolio in Q1 2026, for an estimated $3,038,832
- PROPEL BIO MANAGEMENT, LLC added 1,420,550 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,400,729
- HUDSON BAY CAPITAL MANAGEMENT LP added 869,980 shares (+104.2%) to their portfolio in Q1 2026, for an estimated $1,470,266
- JANE STREET GROUP, LLC removed 563,016 shares (-93.3%) from their portfolio in Q1 2026, for an estimated $951,497
- GOLDMAN SACHS GROUP INC added 389,021 shares (+126.7%) to their portfolio in Q1 2026, for an estimated $657,445
- SEI INVESTMENTS CO added 377,134 shares (+492.2%) to their portfolio in Q1 2026, for an estimated $637,356
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
